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Oxymetholone-Induced Acute Renal Failure:  
A Case Report 
 
 
 
Abstract 
Background: The prevalence of using anabolic steroids such as oxymetholone is 
increasing. This highlights the need for closely monitoring side effects of this drug. Acute 
renal failure (ARF) has been reported as a complication of rhabdomyolysis in anabolic 
steroids users. 
Case presentation: We present one 33-year-old man complaining of decreased urine 
volume, urine color change, and lower abdominal pain.  He is engaged with a rare side 
effect of oxymetholone abuse. During assessments of potential medical issues associated 
with the intake of anabolic steroids, known side effects are known to be transient, but the 
need for appropriate interventions remains essential. 
Conclusions: Rhabdomyolysis due to drug use and the consequent acute kidney injury are 
among the lethal risks associated with anabolic steroid abuse. In most cases, the symptoms 
are extensive and often misleading. Therefore, detailed history taking, physical scrutiny, 
paraclinical testing, and early diagnosis are crucial for rhabdomyolysis patients. 
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Following the isolation and identification of testosterone in 1935, attempts were 
made to synthesize numerous corresponding derivatives (1, 2). Testosterone is 
characterized on the basis of its effects, and testosterone derivatives are known as 
androgenic-anabolic steroids (AASs) because of their functions. Some of the androgenic 
effects of testosterone include the growth of male reproductive system and the 
development of secondary sexual characteristics (3, 4). Its anabolic effects include the 
stimulation of protein synthesis, creation of positive balance between nitrogen 
concentration and muscle growth, enhancement of calcium absorption, stimulation of 
skeletal growth, reduction of body fat, increasing electrolyte uptake, and hematopoiesis 
(3). AASs are also used to treat compensated hypogonadism, catabolic disorders, muscular 
dystrophy, growth retardation, tissue repair, osteoporosis, aplastic anemia, and breast 
carcinoma (3, 5). They can be administered in both oral and injectable forms, such as 
oxandrolone, oxymetholone, methandrostenolone, stanozolol, nandrolone, and decanoate 
(6, 7). The above-mentioned properties of AASs has once motivated professional 
bodybuilders to take these substances, but their use has been gradually spreading among 
other people (1). Most athletes use AASs to achieve a trained physique and increase their 
muscle size, whereas others often employ the substances to enhance libido and augment 
muscle mass (3). According to international reports, the prevalence of AAS use is 3% to 
4% among men and 1.6% among women (1). 
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The increasing prevalence of AAS use highlights the 
need for closely monitoring their side effects, such as 
decreased secretion of sex hormones, testicular atrophy, 
oligoazoospermia, impotence, prostatic hypertrophy, 
gynecomastia in men, menstrual irregularities, clitoral 
hypertrophy, urethral atrophy, atrophy of the female breast, 
liver cell damage, cholestasis, hepatoadenoma, cholesterol 
elevation, hypertension, thrombosis, reduced glucose 
tolerance, acne, alopecia, male pattern baldness, edema, 
hirsutism, and hoarseness (6, 8-10). 
Acute renal failure (ARF) has been reported as a 
complication of rhabdomyolysis in AAS users (1). 
Rhabdomyolysis is defined as the breakdown of muscle 
tissue through the dispersion of intracellular contents into 
extracellular fluid (11). Corresponding clinical consequences 
vary from muscle weakness to life-threatening ARF (12), 
and rhabdomyolysis severity and degree can be diagnosed 
clinically by increasing the concentration of creatinine 
phosphokinase (CPK) (13) and lactate dehydrogenase (LDH) 
(10). A patient with symptoms such as myocyte edema, 
increased intravascular volume, and urine color change to 
reddish-brown is admitted for the clinical diagnosis (13). 
Today, rhabdomyolysis causes ARF in rare cases only (13). 
Rhabdomyolysis occurs for various reasons, including 
poisoning, ischemia, infection and inflammation, severe 
metabolism, and extreme physical activity (10), but it can 
also develop after the intake of certain medications, such as 
steroids; although its incidence is rare, the syndrome is a 
life-threatening phenomenon (11). The renal side effects of 
AASs are infrequent and have been documented only in a 
few cases within some separate reports (14). The next 
section discusses a patient who got engaged with one of the 
rare side effects of anabolic steroids due to oxymetholone 
consumption.  
 
 
Case presentation 
The reported patient was a 33-year-old man complaining 
of decreased urine volume, urine color change, and lower 
abdominal pain. He was admitted to the emergency 
department of a general university hospital in one of the 
northern cities of Iran in winter, 2016. After preliminary 
examinations, he was transferred to the department of 
nephrology for dialysis and other treatments because of high 
levels of urea and creatinine as well as ARF. Because of a 
history of drug dependence, a request for psychiatric 
consultation was submitted to psychiatric service department 
of the hospital. During clinical diagnostic interviews, the 
patient was determined as suffering from substance-related 
disorder and borderline personality disorder on the basis of 
the Axes I and II dimensions, respectively, of the Diagnostic 
and Statistical Manual of Mental Disorders, Fifth Edition 
(DSM-5).  
He had a history of hospitalization for methamphetamine 
rehabilitation, after which the patient turned to methadone, 
tramadol, and opium. To prevent the weight loss caused by 
these drugs, he arbitrarily used oxymetholone for two 
months. The patient was observed for the onset of urinary 
symptoms for four days prior to admission. The first 
laboratory findings for ARF included a urea level of 238 
mg/dL and a creatinine level of 11 mg/dL. Muscle injury and 
rhabdomyolysis were confirmed through the analysis of 
experimental data (myoglobinuria, CPK: 10726 IU/L and 
LDH: 4383 U/L). Concentrations of electrolytes, such as 
potassium and sodium (Na: 130 mEq/L and K: 4.9 mEq/L), 
and serum levels of liver enzymes (alanine transaminase and 
aspartate transaminase) and coagulation factors were normal. 
Liver and kidney ultrasonography was performed shortly 
after hospitalization.  
Liver size and echogenicity were normal. The right 
kidney was 136 mm in size, with a cortical echo and 
increased corticomedullary differentiation. A small amount 
of perinephric fluid was evident around the kidney. The left 
kidney was 102 mm in size, with a normal paranshyal echo 
and reduced focal thickness. Based upon physical 
examination of the patient, the heart, lungs, and nervous 
system showed normal functioning. After diagnostic 
confirmation, the primary therapeutic purpose was to prevent 
ARF risk factors, including the reduction of fluid volume, 
the blocking of tubules, release of free radicals, and aciduria. 
The patient underwent seven rounds of hemodialysis and 
hydration. Eight days after the first day of hospitalization, 
his CPK and LDH levels declined rapidly (CPK: 365 IU/L 
and LDH: 855 U/L). When ARF was settled and the values 
were normal, the patient was discharged. 
 
 
Discussion 
According to the laboratory and clinical symptoms, the 
differential diagnoses for the patient included polymyositis, 
dermatomyositis, mild muscle injury, infection, compartment 
syndrome, rhabdomyolysis, and sickle cell crisis (10). First, 
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the presence of the classic triad of rhabdomyolysis, namely, 
muscle damage, colored urine, and kidney dysfunction, was 
considered in the diagnosis; the diagnosis of ARF caused by 
intoxication with tramadol, methadone, and opium was 
performed. Comprehensiveness of the psychiatric history 
taking and other available details enabled the clinicians to 
determine a history of oxymetholone intake by the patient. 
Nevertheless, the intake of oxymetholone simultaneously 
with methadone, opium, and tramadol did not cause 
rhabdomyolysis—a determination made on the basis of the 
fact that this syndrome involves the breakdown of skeletal 
myocytes, resulting in the release of intracellular contents 
into interstitial fluid and the bloodstream (12). As expected, 
an increase in muscle atrophy-related factors, such as CPK 
and LDH, in the blood was observed (13). In the reported 
case, the absence of fever and leukocytosis negated infection 
are as one of the causes of rhabdomyolysis. Inflammation 
was also rejected because of the lack of increased 
inflammatory markers in the patient’s clinical tests. 
In conclusion During assessments of potential medical 
issues associated with the intake of anabolic steroids, the 
known side effects are known to be transient, but the need 
for appropriate interventions remains essential. Evidence 
suggests that, other influencing factors, such as diet and 
other medications, also largely contribute to serious side 
effects of anabolic steroid intake. Various factors result in 
the development of rhabdomyolysis. Drug-resulted 
rhabdomyolysis and consequent acute kidney injury are 
among the lethal risks associated with anabolic steroid 
abuse; these have remained as mostly unknown and obscure 
risk factors.  
Rhabdomyolysis goes through a very complex 
mechanism that occurs through many compounds; in most 
cases, symptoms are extensive and often misleading. 
Therefore, detailed history taking, physical scrutiny, 
paraclinical testing, and early diagnosis are crucial for 
rhabdomyolysis patients.  
 
 
Acknowledgments 
We would like to thank the staff of the Imam Khomeini 
Hospital in Sari, especially the psychiatry department, as 
well as the patient participants.  
 
Conflict of interest: All the authors declare that there are no 
competing interests. 
 
 
References 
1. El Osta R, Almont T, Diligent C, et al. Anabolic steroids 
abuse and male infertility. Basic Clin Androl 2016; 26: 2. 
2. Kanayama G, Pope HG Jr. History and epidemiology of 
anabolic androgens in athletes and non-athletes. Mol Cell 
Endocrinol 2018; 464: 4-13. 
3. Hoffmann U. Anabolic steroids—a problem in popular 
sports. Toxichem Krimtech 2002; 69: 136-42. 
4. Arazi H, Mohammadjafari H, Asadi A. Use of anabolic 
androgenic steroids produces greater oxidative stress 
responses to resistance exercise in strength-trained men. 
Toxicol Rep 2017; 4: 282-6. 
5. Goldman A, Basaria S. Adverse health effects of 
androgen use. Mol Cell Endocrinol 2018; 464: 46-55. 
6. Maravelias C, Dona A, Stefanidou M, Spiliopoulou C. 
Adverse effects of anabolic steroids in athletes: a 
constant threat. Toxicol Lett 2005; 158: 167-75. 
7. Juhn M. Popular sports supplements and ergogenic aids. 
Sports Med 2003; 33: 921-39. 
8. Mottram DR, George AJ. Anabolic steroids. Baillieres 
Best Pract Res Clin Endocrinol Metab 2000; 14: 55-69. 
9. Wichstrøm L, Pedersen W. Use of anabolic-androgenic 
steroids in adolescence: winning, looking good or being 
bad? J Stud Alcohol 2001; 62: 5-13. 
10. Farkash U, Shabshin N, Pritsch M. Rhabdomyolysis of 
the deltoid muscle in a bodybuilder using anabolic-
androgenic steroids: a case report. J Athl Train 2009; 44: 
98-100. 
11. van Rensburg DCJ, Theron W, Grant TC, Zondi PC, 
Grant CC. Acute corticosteroid-induced rhabdomyolysis 
in a golf player. South Afr J Sports Med 2012; 24: 129-
30. 
12. Coco TJ, Klasner AE. Drug-induced rhabdomyolysis. 
Curr Opin Pediatr 2004; 16: 206-10. 
13. Vanholder R, Sever MS, Erek E, Lameire N. 
Rhabdomyolysis. J Am Soc Nephrol 2000; 11: 1553-61. 
14. Modlinski R, Fields KB. The effect of anabolic steroids 
on the gastrointestinal system, kidneys, and adrenal 
glands. Curr Sports Med Rep 2006; 5: 104-9. 
 
